Dementia and Movement Disorders Market - Global Industry Analysis

Dementia and Movement Disorders Market

Dementia and Movement Disorders Market By Type (Progressive Dementia, Movement Disorder, and Other Neurological Abnormalities), By Drug Class, (Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and Others), By Route of Administration (Parenteral and Oral), By End-Use (Hospitals, Clinics, and Others), By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 18-Jul-2022 Category: Healthcare Report Format : PDF Pages: 216 Report Code: ZMR-3009 Status : Published

The global dementia and movement disorders market size is estimated to grow to about USD 7.45 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period.

Dementia and Movement Disorders Market

Description

Industry Prospective:

The global dementia and movement disorders market size is estimated to grow to about USD 7.45 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period. The report analyzes dementia and movement disorders market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in dementia and movement disorders market.

Dementia and Movement Disorders Market: Overview

Dementia is a broad spectrum of mental diseases that, over time, cause a person's capacity for thought and memory to decrease. The causes of dementia have not yet been discovered, despite advances in science and medicine. As a result, the illness is solely managed on a symptomatic basis. However, it is well established that numerous movement disorders, including Parkinson's, can trigger dementia. They can happen to anyone of any age, from newborns to the elderly. While symptoms in some cases are limited to issues with motor control, in others they can also impact cognitive and autonomic processes.

COVID-19 Impact:

The global dementia and movement disorders market witnessed a drop in revenue with the outbreak of Covid-19. Due to their increased susceptibility to COVID-19, senior individuals with diseases like Alzheimer's disease saw a decrease in their number of clinical visits. However, the prevalence of COVID-19 patients in the country decreased in 2021 as a result of the development of COVID-19 vaccinations. Thus, with accessibility to hospitals and clinics being resumed along with the relaxation of COVID-19-related limitations, the demand for dementia and movement disorders therapy medications increased once again. The global market is therefore anticipated to increase throughout the projected period as a result of these reasons.

Global Dementia And Movement Disorders Market

Dementia and Movement Disorders Market: Growth Drivers

Rising geriatric population to fuel the market expansion.

The rising geriatric population is one of the main factors promoting the growth of global dementia and movement disorders market. Children under the age of five have been outnumbered by persons 60 years and older in the year 2020. Eighty percent of the world's elderly population will reside in low- and middle-income nations by 2050. On an account of this, it is anticipated that there would be 78 million cases of dementia worldwide by 2030 and 139 million cases by 2050. Globally rising senior populations will raise the likelihood that people may have neurological conditions like dementia, which will increase demand for dementia medications and propel the market.

Dementia and Movement Disorders Market: Restraints

High costs associated with the treatment to hamper the market growth

The growing financial burden of neurological illnesses is one of the main reasons impeding the market's expansion for treatments for dementia and movement disorders. One of the 10 major leading causes of mortality in the US, according to the CDC, is Alzheimer's disease. As a result, the US has a significant need for Alzheimer's disease treatment. Patients in the US, however, face difficulties as a result of rising treatment expenses. The Michael J. Fox Foundation and other national organizations in the US completed and released research titled The Economic Burden of Parkinson's Disease. According to the report, Parkinson's disease costs the US government, families, and people a total of $51.9 billion every year. Thus, high costs and increasing economic burden are the factors hindering the growth of global market.

Dementia and Movement Disorders Market: Opportunities

Heavy investments in R&D activities to foster market expansion during the forecast period

Dementia correlated with Alzheimer's disease is anticipated to see growth over the course of the forecast period as a result of increasing disease-modifying therapeutic R&D activities and increased investments by major players in clinical trials of cutting-edge treatment alternatives. In addition to this, mergers and acquisitions as well strategic collaborations by big pharma for business expansion are also likely to generate numerous opportunities for the growth of global dementia and movement disorders market during the forecast period.

Dementia and Movement Disorders Market: Challenges.

Stringent regulatory framework to act as a challenge to market growth

Even though there is a lot of work being done to help those with dementia and movement disorders, the market is facing profound challenges due to the regulatory framework's strictness, the lengthy approval process for drugs, the lack of funding for research & development, and the inadequate therapeutic management techniques. Additionally, the majority of disease-treatment medications fail Phase III testing, rendering efforts futile and reverting the issue of treating these disorders to its original state.

Dementia and Movement Disorders Market: Segmentation

The global dementia and movement disorders market is categorized based on type, drug class, route of administration, end use, and region. Based on the type, the market is fragmented into progressive dementia, movement disorder, and other neurological abnormalities. Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and others are included in the drug class segment. The route of administration market comprises parenteral and oral. The end-use segment is classified into hospitals, clinics, and others.

During the anticipated period, the MAO inhibitors market share will expand significantly in terms of treating dementia and movement disorders. MAO inhibitors are utilized as monotherapy in initial Parkinson's disease or as an additional treatment in individuals with motor-related Parkinson's disease symptoms due to their excellent effectiveness and specificity. Thus, it is anticipated that the use of MAO inhibitors would rise as Parkinson's disease and other associated conditions become more common.

Recent Developments

  • In June 2022, in order to create and market AL01811, a new preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying therapy for Parkinson's disease patients, Biogen and Alectos Therapeutics have engaged in a licensing and partnership agreement. Through this partnership, Biogen's ability to create treatments for movement disorders will be combined with Alectos' expertise in small-molecule therapies.
  • In July 2021, GSK and Alector announced a strategic collaboration to produce progranulin-elevating monoclonal antibodies, AL001 and AL101, for a variety of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Dementia and Movement Disorders Market: Regional Landscape

North America to dominate the global market during the forecast period

Among the regions, North America is estimated to lead global dementia and movement disorders market. During the projection period, North America will account for 48% of market growth. The largest market in North America for the treatment of dementia and movement disorders are the US and Canada. Compared to the rest of the world, this region's market will increase more rapidly. Over the projection period, dementia and movement disorder therapy market would rise in North America due to the rising incidence of target illnesses including Parkinson's disease and Alzheimer's disease. On the other hand, due to government financial backing for enhancing quality healthcare infrastructure in numerous countries throughout the region and the intensifying campaigns for promoting consciousness of the therapies for dementia and movement disorders, the treatment procedures, and their effect on mental health, Asia Pacific may also present enormous opportunities for the market growth during the forecast period.

Dementia and Movement Disorders Market: Competitive Landscape

Novartis AG, Merck and Co. Inc., Biogen Inc., Bausch Health Companies Inc., Acorda Therapeutics Inc., AbbVie Inc., Johnson and Johnson, GlaxoSmithKline Plc, Eisai Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major players operating in global dementia and movement disorders market.

Global dementia and movement disorders market is segmented as follows:

By Type

  • Progressive Dementia
  • Movement Disorder
  • Other Neurological Abnormalities

By Application

  • Glutamate inhibitors
  • Acetylcholinesterase inhibitors
  • MAO inhibitors
  • Others

By Route of Administration

  • Parenteral
  • Oral

By End User

  • Hospitals
    • Clinics
    • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

The rising geriatric population is one of the main factors promoting the growth of global dementia and movement disorders market. Globally rising senior populations will raise the likelihood that people may have neurological conditions like dementia, which will increase demand for dementia medications and propel the market.

According to the Zion Market Research report, global dementia and movement disorders market is predicted to grow to around 7.45 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 6.5 percent.

Among the regions, North America is estimated to lead global dementia and movement disorders market. During the projection period, North America will account for 48% of market growth. The largest market in North America for the treatment of dementia and movement disorders are the US and Canada. Compared to the rest of the world, this region's market will increase more rapidly. Over the projection period, dementia and movement disorder therapy market would rise in North America due to the rising incidence of target illnesses including Parkinson's disease and Alzheimer's disease.

Novartis AG, Merck and Co. Inc., Biogen Inc., Bausch Health Companies Inc., Acorda Therapeutics Inc., AbbVie Inc., Johnson and Johnson, GlaxoSmithKline Plc, Eisai Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major players operating in the global dementia and movement disorders market.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed